
## Gian Luca De Salvo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1173768/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	10.7	717
2	A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer. Annals of Surgery, 2008, 247, 207-213.	4.2	277
3	Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution's Experience with 52 Patients. Annals of Surgical Oncology, 2009, 16, 191-199.	1.5	256
4	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	10.7	238
5	Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella–GIVOM Italian randomised clinical trial. European Journal of Surgical Oncology, 2008, 34, 508-513.	1.0	175
6	Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1566-1575.	10.7	161
7	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq1 I 19, 1061-1071.	0.784314 10.7	rgBT /Overlo 137
8	Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status. Journal of the National Cancer Institute, 2006, 98, 285-288.	6.3	123
9	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. European Journal of Cancer, 2011, 47, 724-731.	2.8	123
10	Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI). Annals of Surgical Oncology, 2009, 16, 2018-2027.	1.5	121
11	Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Annals of Oncology, 2015, 26, 567-572.	1.2	115
12	Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Cancer, 2004, 101, 1664-1671.	4.1	113
13	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (â‰⊉6Âyears) low grade glioma– A final report. European Journal of Cancer, 2017, 81, 206-225.	2.8	104
14	The challenge of very rare tumours in childhood: The Italian TREP project. European Journal of Cancer, 2007, 43, 654-659.	2.8	98
15	Therapy of hepatitis C: Re-treatment with alpha interferon. Hepatology, 1997, 26, 137S-142S.	7.3	96
16	Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupÂexperience. European Journal of Cancer, 2016, 57, 1-9.	2.8	94
17	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. European Journal of Surgical Oncology, 2016, 42, 1914-1923.	1.0	89
18	Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut, 1998, 42, 856-860.	12.1	81

#	Article	IF	CITATIONS
19	Pancreatic tumors in children and adolescents: The Italian TREP project experience. Pediatric Blood and Cancer, 2010, 54, 675-680.	1.5	75
20	Inflammatory myofibroblastic tumors in childhood. Cancer, 2010, 116, 216-226.	4.1	71
21	Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). European Journal of Cancer, 2020, 127, 123-129.	2.8	71
22	Curative surgery for obstruction from primary left colorectal carcinoma: Primary or staged resection?. The Cochrane Library, 2004, , CD002101.	2.8	67
23	Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node. Annals of Surgical Oncology, 2008, 15, 1202-1210.	1.5	64
24	Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study—EpSSG NRSTS 2005. European Journal of Cancer, 2016, 60, 69-82.	2.8	63
25	Prognostic factors in pleuro-pulmonary blastoma. Pediatric Blood and Cancer, 2007, 48, 318-323.	1.5	62
26	Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group. European Journal of Cancer, 2017, 78, 1-6.	2.8	62
27	Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. European Journal of Surgical Oncology, 2005, 31, 715-720.	1.0	61
28	Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Annals of Oncology, 2014, 25, 231-236.	1.2	61
29	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. European Journal of Cancer, 2003, 39, 1577-1585.	2.8	56
30	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. British Journal of Cancer, 2011, 104, 1816-1821.	6.4	53
31	Evaluating access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: The TREP project. Pediatric Blood and Cancer, 2009, 53, 152-155.	1.5	52
32	Fusion status in patients with lymph nodeâ€positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer, 2018, 124, 3201-3209.	4.1	51
33	Health-Related Quality of Life Outcomes in Disease-Free Survivors of Mid-Low Rectal Cancer After Curative Surgery. Annals of Surgical Oncology, 2008, 15, 1846-1854.	1.5	50
34	Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. Supportive Care in Cancer, 2010, 18, 601-608.	2.2	50
35	Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Letters, 2001, 168, 31-36.	7.2	49
36	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncology, 2021, 23, 264-276.	1.2	48

#	Article	IF	CITATIONS
37	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. Journal of Pediatrics, 2014, 164, 376-382.e2.	1.8	47
38	Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. Aids, 2000, 14, 1721-1729.	2.2	44
39	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research, 2017, 23, 3316-3324.	7.0	43
40	The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. The Lancet Child and Adolescent Health, 2017, 1, 284-292.	5.6	43
41	Adrenocortical tumors in Italian children: Analysis of clinical characteristics and P53 status. Data from the national registries. Journal of Pediatric Surgery, 2014, 49, 1367-1371.	1.6	42
42	Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. Annals of Surgical Oncology, 2005, 12, 398-405.	1.5	41
43	Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. European Journal of Cancer, 2012, 48, 3448-3455.	2.8	41
44	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	6.4	41
45	Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups. Pediatric Blood and Cancer, 2018, 65, e27096.	1.5	40
46	Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTSâ€⊋005 prospective study. Pediatric Blood and Cancer, 2019, 66, e27833.	1.5	40
47	Local lymph node involvement in pediatric renal cell carcinoma: A report from the Italian TREP project. Pediatric Blood and Cancer, 2008, 51, 475-478.	1.5	39
48	Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. European Journal of Surgical Oncology, 2006, 32, 1201-1208.	1.0	36
49	Features predicting unresectability in hepatoblastoma. Cancer, 2007, 110, 1050-1058.	4.1	36
50	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clinical Cancer Research, 2022, 28, 308-317.	7.0	36
51	The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Research, 2005, 15, 191-198.	1.2	34
52	A multidisciplinary approach to improve preoperative understanding and reduce anxiety. European Journal of Anaesthesiology, 2013, 30, 734-742.	1.7	34
53	Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatric Blood and Cancer, 2017, 64, e26348.	1.5	32
54	Clinical impact of false-negative sentinel lymph nodes in breast cancer. European Journal of Surgical Oncology, 2008, 34, 620-625.	1.0	31

#	Article	IF	CITATIONS
55	The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). Journal of Nuclear Medicine, 2006, 47, 234-41.	5.0	31
56	Sentinel node mapping andÂbiopsy inÂthyroid cancer: aÂsurgical perspective. Biomedicine and Pharmacotherapy, 2006, 60, 405-408.	5.6	29
57	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. Oncotarget, 2017, 8, 6433-6445.	1.8	29
58	Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG). The Lancet Child and Adolescent Health, 2021, 5, 546-558.	5.6	28
59	Number of Metastatic Sentinel Nodes As Predictor of Axillary Involvement in Patients with Breast Cancer. Breast Cancer Research and Treatment, 2004, 86, 171-179.	2.5	27
60	Pediatric patients with cutaneous melanoma: A European study. Pediatric Blood and Cancer, 2018, 65, e26974.	1.5	26
61	Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. European Journal of Cancer, 2012, 48, 1370-1375.	2.8	25
62	Childhood Leukemia and 50 Hz Magnetic Fields: Findings from the Italian SETIL Case-Control Study. International Journal of Environmental Research and Public Health, 2015, 12, 2184-2204.	2.6	25
63	Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group. Journal of Clinical Oncology, 2019, 37, 723-730.	1.6	24
64	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Journal of Clinical Oncology, 2018, 36, LBA2-LBA2.	1.6	23
65	Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]. BMC Cancer, 2006, 6, 44.	2.6	22
66	Contribution of SLN investigation with 99mTc-nanocolloid in clinical staging of thyroid cancer: technical feasibility. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 934-938.	6.4	22
67	Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience. Cancer Medicine, 2018, 7, 1384-1393.	2.8	22
68	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. Oncologist, 2019, 24, 1424-1431.	3.7	22
69	Psychological wellâ€being outcomes in diseaseâ€free survivors of midâ€ŀow rectal cancer following curative surgery. Psycho-Oncology, 2011, 20, 706-714.	2.3	21
70	Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2018, 65, e26942.	1.5	21
71	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. Journal of Clinical Oncology, 2018, 36, 3466-3476.	1.6	21
72	Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. European Journal of Cancer, 2019, 112, 98-106.	2.8	21

#	Article	IF	CITATIONS
73	ls surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. Cancer, 2020, 126, 823-831.	4.1	21
74	Colonic J-Pouch or Straight Colorectal Reconstruction After Low Anterior Resection For Rectal Cancer: Impact on Quality of Life and Bowel Function: A Multicenter Prospective Randomized Study. Diseases of the Colon and Rectum, 2020, 63, 1511-1523.	1.3	21
75	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Clioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research, 2020, 26, 4478-4484.	7.0	20
76	Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. European Journal of Cancer, 2021, 146, 21-29.	2.8	20
77	Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast cancer? Early interruption of a phase II study. Annals of Oncology, 2007, 18, 58-63.	1.2	19
78	Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS ONE, 2013, 8, e80456.	2.5	19
79	Self-efficacy for coping: utility of the Cancer behavior inventory (Italian) for use in palliative care. BMC Palliative Care, 2019, 18, 34.	1.8	18
80	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. European Journal of Cancer, 2020, 130, 72-80.	2.8	18
81	The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. Expert Review of Anticancer Therapy, 2012, 12, 243-254.	2.4	16
82	Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSGâ€RMS2005 study. Cancer Medicine, 2020, 9, 7580-7589.	2.8	16
83	DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. Cancer Letters, 2011, 310, 84-93.	7.2	15
84	Analysis of technical and clinical variables affecting sentinel node localization in patients with breast cancer after a single intradermal injection of 99mTc nanocolloidal albumin. Nuclear Medicine Communications, 2004, 25, 1119-1124.	1.1	14
85	Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters. Journal of Immunology, 2006, 176, 1999-2006.	0.8	14
86	Paratesticular rhabdomyosarcoma—Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG). Pediatric Blood and Cancer, 2020, 67, e28479.	1.5	13
87	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Pediatric Blood and Cancer, 2021, 68, e28832.	1.5	13
88	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). European Journal of Cancer, 2021, 155, 179-190.	2.8	13
89	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. Pigment Cell and Melanoma Research, 2011, 24, 728-730.	3.3	12
90	Sentinel-Node Biopsy in Breast Cancer. New England Journal of Medicine, 2003, 349, 1968-1971.	27.0	11

#	Article	IF	CITATIONS
91	Outcome of localized liverâ€bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Softâ€Tissue Sarcoma Study Group (EpSSC)â€RMS 2005 study. Pediatric Blood and Cancer, 2019, 66, e27725.	1.5	11
92	Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2020, 67, e28351.	1.5	11
93	The unconventional Di Bella cancer treatment. , 1999, 86, 1903-1911.		10
94	5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results. Archives of Medical Research, 2006, 37, 860-865.	3.3	10
95	Family History of Cancer Rather Than p53 Status Predicts Efficacy of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1022-1028.	2.5	10
96	Sentinel node biopsy for breast cancer: is it already a standard of care? A survey of current practice in an Italian region. BMC Cancer, 2004, 4, 2.	2.6	9
97	First Prospective Multicenter Italian Study on the Impact of the 21â€Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. Oncologist, 2018, 23, 297-305.	3.7	8
98	Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. Clinical Cancer Research, 2020, 26, 2921-2931.	7.0	8
99	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study Journal of Clinical Oncology, 2018, 36, 507-507.	1.6	6
100	Phase I–II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Research, 2003, 13, 293-297.	1.2	4
101	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS) Journal of Clinical Oncology, 2018, 36, 2047-2047.	1.6	4
102	Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. , 1998, 54, 7-11.		3
103	Clinical and molecular detection of inherited colorectal cancers in northeast Italy. Tumor Biology, 2012, 33, 857-864.	1.8	3
104	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS) Journal of Clinical Oncology, 2017, 35, TPS2085-TPS2085.	1.6	3
105	A model to predict long-term sustained response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis, 1997, 4, 193-197.	2.0	2
106	A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors' reply. Lancet Oncology, The, 2020, 21, e3.	10.7	2
107	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208–16. European Urology Oncology, 2020, 3, 713.	5.4	2
108	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients Journal of Clinical Oncology, 2019, 37, 2045-2045.	1.6	2

#	Article	IF	CITATIONS
109	Insufficient evidence to compare clinical effectiveness and safety of self-expanding metal stents with other treatments for malignant colorectal obstruction. Cancer Treatment Reviews, 2005, 31, 226-229.	7.7	0
110	Predictors of unresectability in hepatoblastoma: A 20-year single centre report. Digestive and Liver Disease, 2007, 39, A69.	0.9	0
111	First prospective multicenter Italian study on the impact of the 21-gene recurrence score® (RS) in adjuvant clinical decisions for ER + /HER2- early breast cancer patients. Annals of Oncology, 2016, 27, vi53.	1.2	0
112	First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients Journal of Clinical Oncology, 2017, 35, e12038-e12038.	1.6	0
113	Genomic index in pediatric synovial sarcoma (SYNOBIO study): The European Pediatric Soft Tissue Sarcoma Group (EpSSG) experience Journal of Clinical Oncology, 2017, 35, 10529-10529.	1.6	0
114	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results Journal of Clinical Oncology, 2018, 36, e24074-e24074.	1.6	0